Tralokinumab-ldrm side effects

Generic Name: tralokinumab-ldrm

Brand name: Adbry

What is Tralokinumab-ldrm?

Before making use of this medication

Before beginning treatment, inform your doctor about your medical condition and conditions, such as if:


How can I use it?

Tralokinumab-ldrm side effects

Tralokinumab-ldrm side effects

Tralokinumab-ldrm side effects are the unwanted effects that may be experienced  when we use this drug

The most commonly reported adverse effects are:


  • Hypersensitivity reactions, such as anaphylaxis and angioedema, have been documented using Tralokinumab-ldrm.
  • If a severe hypersensitivity reaction develops, stop taking Tralokinumab-ldrm right away and immediately begin treatment.

Conjunctivitis and Keratitis

  • Keratitis and conjunctivitis were seen more often in atopic patients who had received Tralokinumab-ldrm. Conjunctivitis was by far the most commonly diagnosed eye problem. A majority of those suffering from conjunctivitis, or keratitis were either healed or recuperating during the course of treatment.
  • Encourage patients to report any onset of new or worsening symptoms to their physician.

Parasitic (Helminth) Infections

  • Patients with helminth infection history have been excluded from participating in clinical trials. It is unclear whether Tralokinumab-ldrm can affect the immune response to the helminth infection by reducing the signaling of IL-13.
  • For patients who have already-existing helminth infection prior to initiating the treatment using Tralokinumab-ldrm. If patients contract a helminth infection during treatment with Tralokinumab-ldrm and are not responding to antihelminth therapy, discontinue the treatment using Tralokinumab-ldrm till the infection is gone.

Risk of Infections via Live Vaccines

  • Tralokinumab-ldrm could alter the immune system of a patient and increase the chance of getting sick following vaccination with live vaccines. Prior to starting treatment using Tralokinumab-ldrm, be sure to complete all age-appropriate vaccinations in accordance with the latest immunization guidelines. Do not use live vaccines for patients being treated with Tralokinumab-ldrm. The data available are limited regarding the coadministration of Tralokinumab-ldrm using non-live vaccines

This is not the only list of the possible adverse consequences. Consult your physician to seek medical advice on possible side effects. You can report any symptoms to FDA by calling 800-FDA-1088.

General information on the safety

Some medicines are used for reasons other than those stated in the Patient Information leaflet. Use this medicine only to treat a health condition for which it was not recommended. Don’t give it to others regardless of whether they are suffering from similar symptoms to yours. It could harm them. It is possible to ask your doctor or pharmacist for advice that has been specifically written for health professionals.

How supplied


  • 150 mg/mL per syringe, x 2
  • Rx only
  • For Subcutaneous Use Only
  • Two 1-mL single-dose prefilled syringes equal 300 mg
  • Carton contains:
    • Two 1-mL single-dose prefilled syringes with the needle guard
    • Prescribing Information
    • Instructions for Use and Patient Information
Tralokinumab-ldrm side effects



  • 150 mg/mL per syringe, x 4
  • Rx only
  • For Subcutaneous Use Only
  • Four 1-mL single-dose prefilled syringes equal 600 mg
  • Multipack contains:
    • Two cartons
    • Each carton contains two 1-mL single-dose prefilled syringes
      with needle guard which equal 300 mg

Additional details

Always consult your physician to confirm that the information provided on this page is applicable to your specific situation.

Leave a Reply